

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055559 A1

(51) International Patent Classification⁷: **C07K 16/00**

(21) International Application Number: PCT/IT01/00014

(22) International Filing Date: 15 January 2001 (15.01.2001)

(25) Filing Language: Italian

(26) Publication Language: English

(71) Applicants and

(72) Inventors: **FAZIO, Vito, M.** [I/I/IT]; Via del Caucaso, 49, I-00100 Roma (IT). **SAGLIO, Giuseppe** [IT/IT]; Corso Peschiera, 248, I-10139 Torino (IT).

(74) Agents: **PISTOLESI, Roberto**; Dragotti & Associati S.r.l., Galleria San Babila, 4/C, I-20122 Milano et al. (IT).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,

DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DNA VACCINES EXPRESSING HYPERVARIABLE VH-CDR3 IDIOTYPIC DETERMINANTS

(57) Abstract: The present invention relates to a method for inducing the immune response of an individual against B-lymphoproliferative disorders. The method is based on DNA vaccination with the short peptide encompassing the CDR3 hypervariable region of immunoglobulin heavy chain (VH-CDR3) alone or in combination with at least another immunomodulating sequence.



WO 02/055559 A1

DNA vaccines expressing hypervariable VH-CDR3 idiotypic determinants

The present invention relates to a method for inducing the immune response of an individual against B-lymphoproliferative disorders; the method is based on DNA vaccination with the short peptide encompassing the CDR3 hypervariable region of immunoglobulin heavy chain (VH-CDR3) alone or in combination with at least another immunomodulating sequence.

Background of the invention

B cell lymphomas are neoplasms of mature lymphocytes which generally express immunoglobulin (Ig) on the cell surface. The Igs are clone specific and the variable regions contain determinants which may themselves be recognized as antigens or idiotopes. The idiotypic Ig therefore represents a unique tumor-specific antigen. (Wen YJ., et al. Eur.J.Immunol. 1997. 27: 1043-1047).

Traditional treatments, such as chemotherapy and radiation therapy, can both induce remission in patients with low grade non-Hodgkin's lymphoma (NHL). However, despite this responsiveness to treatment, the majority of patients ultimately relapse and cannot be cured with these standard therapies and long-term outlook for this patients remains poor.

It is likely that the disease is essentially incurable, except may be by allogenic bone marrow transplantation. As the number of patients who would be suitable for such a therapeutic modality is extremely small, alternative methods of treatment are needed. An attractive approach would be to evoke the ability of the immune system to recognize and eliminate neoplastic cells while sparing normal cells.

B-cell lymphomas represent ideal models for experimental tumor immunotherapy. In fact the Ig's idiotypes displayed on their cell surface represent attractive tumoral antigens since they are tumor-specific, belong to a well known family of molecules and it has been demonstrated that idiotypic-specific immune response can be obtained also for self Igs. However, the efficacy of the anti-idiotypic vaccination is likely to be more effective in some histotypes than in others. Low grade B-cell lymphomas, as those with a small lymphocytic or follicular histotype, are expected to represent ideal targets because they i) generally show an indolent behaviour and are difficult to eradicate; ii) present a very low degree of

clonal evolution; iii) express surface Igs at high levels; iii) do not secrete surface immunoglobulins.

On the other hand, anti-idiotypic vaccination is expected to be less effective against lymphoblastoid and other high-grade lymphomas, which do not express immunoglobulins on the surface; moreover, these types are very aggressive and may show a high degree of clonal evolution (30-40%).

Although the traditional approach to immunization, i.e., sub-cutaneous immunization with the whole immunoglobulin by B-cell lymphoma mixed with adjuvant, was proven to be effective both in experimental models (George et al. J. Immunol., 138: 2168-2174, 1988), as well as in controlled clinical trials (Kwak et al. N. Engl. J. Med., 327: 1209-1215, 1992), such an approach was hampered by the need of the high amounts of purified protein that have to be prepared and certified for each case.

Several reports have indicated that the immunodominant epitopes of the clone specific Ig lies within the hypervariable regions and mainly within the third complementary determining region of immunoglobulin heavy chain (VH-CDR3) (Campbell et al. J. Immunol., 139: 2825-2833, 1987/Watanabe et al. J. Immunol., 151: 2871-2876, 1993). Furthermore, many observations suggest that immunization with whole protein may in some case produce an antibody response restricted to short linear epitopes, and consequently inadequate, rather than recognizing the three-dimensional structure of the protein itself (Kawaguchi et al. J. Biol. Chem., 264: 5762-5767, 1989). Conversely, immunization with short peptides (8-20 aa residues long) can result in production of antibodies that recognize the corresponding linear epitope on a protein without need for conjugation to carriers, provided that the short peptide behaves as a complete antigen (i.e. contains sequences able to bind Class II MHC molecules and to engage the T-cell receptor).

Indeed, it was demonstrated that a short peptide encompassing the VH-CDR3 region of a human lymphoma specific IgM was able to promote the *in vitro* proliferation of specific CD4+ and CD8+ cells, capable to lyse the autologous lymphoma cells (Wen et al. Eur. J. Immunol., 27: 1043-1047, 1997). The clinical relevance of these results obtained *in vitro* was confirmed by the specific immune

response obtained in a patient following vaccination with the peptide (Wen et al. *Br. J. Haematol.*, *103*: 663-668, 1998).

The development of the method of vaccination by means of direct injection of naked DNA into the muscle or subcutaneously, combined with the ability of easily identifying and cloning individual tumor-specific idiotypes, has improved the chances of exploiting these tumor antigens. This approach has already proven effective in inducing immune responses to several antigens mainly of viral origin, and it has been applied to therapy of experimental murine lymphomas where the Ig characterizing the lymphoma has been used for immunotherapy of the parental tumor via DNA based vaccination (Hawkins et al. *Blood*, *83*: 3279-3288, 1994/Fazio V. M. *Res. Virol.*, *148*: 101-108, 1997/Stevenson et al. *Immunol. Rev.*, *145*: 211-228, 1995). Such a method has proven effective in eliciting anti-idiotypic specific immune responses when whole Ig, or its variable regions engineered to be expressed on non-self Ig (Syringelas et al. *Nature Med.*, *2*: 1038-1041, 1996), germ-line light chains (Watanabe et al. *J. Immunol.*, *151*: 2871-2876, 1993) or toxin fusion protein (King et al. *Nature Med.*, *11*: 1281-1286, 1998) were used as encoded antigen.

Nevertheless, if this technology were to be transferred to clinical practice, such a time consuming work would still be needed for each patient to render this approach too expensive to be carried out on a regular clinical basis.

An efficient and cheap DNA-based method for inducing an immune response against B-lymphoproliferative disorders would be desirable; in particular if we consider that purified double strand DNA itself is not immunogenic (Parker SE, Borellini F. et al. *Hum. Gene Ther.*, *10* (5): 741-58, 1999). Moreover, if we consider that the calculate rate of mutation would be 3000 times less than spontaneous mutation rate for mammalian genomes, the level of integration, if should occur, would not be considered to pose a significant safety concern. (Martin T., Parker SE, et al. *Hum. Gene Ther.* *10* (5): 759-68).

Description of the invention

It has now surprisingly been found that an efficient, safe and easily reproducible DNA-based immune response against B-lymphoproliferative pathologies can be achieved upon administration to the patient of a plasmid containing a DNA

sequence essentially coding for a short peptide encompassing the hypervariable region of idiotypic immunoglobulin heavy chain (VH- CDR3).

It has also been found that a multi-gene expression vector, whose principal characteristic is the coexistence of two distinct, complete and differentially regulated transcription units, allowing the co-expression of an immunomodulatory molecule, preferably human interleukin-2 (IL2), and of the CDR3 hypervariable region of idiotypic immunoglobulin heavy chain, remarkably increases the above-mentioned immune response.

The main object of the present invention is therefore represented by the use of the DNA sequence coding for the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders as a vaccine (or for the manufacture of a vaccine composition), said vaccine being effective against chronic B-lymphoproliferative disorders expressing the surface idiotypic immunoglobulin in mammals.

According to a preferred embodiment of the invention, said DNA sequence codes for peptides having a length of 0-45 a.a., preferably of 7-45 a.a.; said DNA sequence is comprised between eFW3 and eJH sequences and corresponds to VH-CDR3 sequence.

A second object of the invention is represented by a recombinant plasmid expression vector suitable for expression of a DNA sequence in a mammalian and containing a DNA sequence operably linked thereto, characterized in that said DNA sequence essentially consists of the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders in a mammalian; as above indicated such a sequence is usually of 7-45 a.a.

The plasmid which can be used for the purposes of the present application can be selected from multigenic vectors which incorporate two different transcription cassettes controlled by two independent promoters, preferably CMV and RSV promoter/enhancers, and allow co-expression of a cytokine or an immunotoxin, such as human IL-2, GM-CSF or IL-6, together with a specific antigen, namely the individual VH-CDR3 peptide.

According to an embodiment of the invention, said recombinant plasmid expression vector encodes also for an immunomodulatory molecule which can be for instance selected from IL-2, GM-CSF, IL-12, IL-6, or for a fragment from bacterial immunotoxins such as the tetan toxin.

According to a further embodiment of the invention, said DNA sequence consists of: (a) the gene coding for the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders and (b) upstream and downstream PCR primers; preferably, said upstream PCR primer is eFW3 whereas said downstream PCR primer is eJH.

A third object of the invention is then represented by a vaccine composition containing such a recombinant plasmid expression vector, said vaccine composition being preferably in a form suitable form being administered parenterally, more preferably intramuscularly, such for instance a water solution.

The investigation which permitted to make the present invention addressed the question of whether different short peptides encompassing the VH-CDR3 hypervariable region of the lymphoma/leukemia surface immunoglobulin usually, but not limited, between 7-45 aa., expressed by direct intramuscular injection of the corresponding mini-genes, might be efficiently presented to the immune system of different outbred mouse, to generate antibodies able of reacting with patient's tumor cells exposing the specific idiotypic protein; the xenogenic, outbred mouse model was decided to mimic the MHC-1 variability present in a clinical setting without immunizing human subjects.

Restriction to the individual CDR3 region excluded xenogenic or allogenic epitopes contained in the variable as well as in the constant region of the idiotypic immunoglobulin, greatly enhancing the safety margin when this approach is transferred in a syngenic context.

A double-gene plasmid vector for the co-expression of the specific individual CDR3 sequences and of an immuno-modulating cytokine, i.e.IL-2, was selected as the vehicle for the intramuscular injection.

Such a vector was deemed to improve the safety by linking the expression of the cytokine to the expression of the foreign antigen in the same cells; this strategy ensures in fact the production of the immuno-modulating molecule only when and

where needed, that is as long as the foreign antigen itself is produced. It was believed that it would have been unlikely that T cells responsive to a protein (IL2), that is involved in all immune responses and is present at high concentration any time T cells are activated, could survive the induction of tolerance.

As a matter of fact, to our knowledge, there was only one report showing the possibility to induce anti-IL-2 antibodies in mice, but the protocol required immunization with a form of the IL-2 that was truncated and contained amino acid substitution (Matesanz et al. *Autoimmunity*, 12: 221-227, 1999).

It was thus found that up to 60 % of outbred animals injected with each VH-CDR3/IL2 co-expressing plasmid vectors mounted a significant, rapid immune response that lasted at least for 19 weeks after the first DNA injection. The number of responding animals declined up to 20 % in the absence of IL2 co-stimulation. More importantly, all VH-CDR3 immune animals developed antibody response able to recognize the entire idiotypic immunoglobulin exposed on the patient-derived lymphoma/leukemia-cells, as demonstrated by FACS analysis.

No cross reactivity was found when immune sera of each VH-CDR3 were challenged with tumor cells of other patients. A possible interpretation of these results is that DNA vaccination by VH-CDR3 linear short peptides may induce production of antibodies which identify specific linear epitopes on the folded idiotypic immunoglobulin.

The currently accepted mechanism of DNA vaccination by intramuscular plasmid injection suggests that the priming is performed by bone marrow-derived antigen-presenting cells (APC), which are efficient at providing all of the necessary signals for priming the T cells. The muscle cells participate in the immunization mechanism as a reservoir for the antigen and a persisting immune stimulus, due to the long-term stability of muscle fibers and transgene expression. The method of DNA vaccination and the form of DNA-expressed antigen may bias T-cell help to primarily type-1 or type-2.

The proposed experimental model includes both intramuscular injection and non secreted peptides which may direct the response to the Th1 pathway. Moreover,

IL2 expression may function by enhancing T-cell-mediated immune response and by improving antigen specific T cell proliferation, as well as differentiation and Ig secretion of antigen-activated B-cells.

In this context, antibody response may be generated by B-cell stimulation obtained by peptides released from muscle cells during immune-mediated destruction of transfected muscle fibers.

Several reports suggested that the mechanism of protection against low grade lymphoma is likely to be antibody-mediated (Dyke et al. Cell. Immunol., 132: 70-83, 1991), possibly due to direct induction of apoptosis (Vitetta et al. Blood, 89: 4425-4436, 1997). Very recently experimental data confirmed that tumor-protective effects of DNA vaccination can be mainly ascribed to idiotype-specific humoral immunity (Syrengeles et al. J. Immunol., 1162: 4790-4795, 1999), and still more convincingly prolonged survival in a clinical trial has been correlated with the induction of anti-idiotypic antibody responses.

However, the nature of a protective immune-response in already established low-grade B-cell lymphomas is still debated and other studies call for a correlation between cell-mediated cytotoxicity and therapeutic response (Nelson et al. Blood, 88: 580-589, 1996). In this outbred experimental model the idiotypic peptides are neither secreted nor intravenously injected, but directly produced without specific signals (i.e., leader sequence for secretion) in *in vivo* transfected cells, in combination with recombinant IL2 expression.

This mechanism may warrant for antibody production and cytotoxic response, without the impairment associated with the binding of anti-idiotypic VH-CDR3 antibodies to the secreted peptide or to the injected peptidic vaccine.

Even if the VH-CDR3 region of the idiotypic immunoglobulin is most variable and therefore most likely to be unique to this protein, most of the somatic mutations that may develop under the immune pressure are clustered in the CDR1, CDR2 and framework 3 (FR3) regions of the idiotypic protein. (Berek C., Milstein C. Immunol. Rev.96: 23-41.1987).

Due to the ease in identifying new VH-CDR3 idiotypic variants as well as in rapidly cloning and manufacturing clinical-grade DNA vaccine preparations, the

proposed protocol may anyway be re-applied in the follow-up of the treated patient.

In conclusion, the immune responses generated by naked DNA immunization in an outbred animal model prove the potential immunogenicity and a large margin of safety of the VH-CDR3 mini-gene encoded peptides, and provide the basis for the vaccination of human patients affected by B-lymphoproliferative disease. This approach in fact avoids xenogenic or allogenic epitopes contained in the variable as well as in the constant region of the idiotypic immunoglobulin, enhancing the safety margin of this molecular approach.

Moreover, the xenogenic outbred experimental model can more closely reproduce the patient setting and the immune response variability, because it mimics the MHC-1 variability present in a clinical setting without immunizing directly human subjects.

According to this invention, it will be now possible to vaccinate humans affected by B-lymphoproliferative disorders by (i) isolating the patient's DNA sequence coding for the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells (ii) cloning said sequence into the mentioned expression plasmid (iii) administering the so obtained recombinant expression plasmid to the patient, preferably via intramuscular injection.

These and other aspects of the present invention will be clarified by the following experimental portion, whose purpose is to illustrate the invention without constituting a limitation of the field of application thereof.

Legend

For the purposes of the present application the following abbreviations have been used: CDR3, complementary determining region 3; Ig, immunoglobulin; VH, variable immunoglobulin heavy chain; mIL2, mouse interleukin-2; FRW, framework; GM-CSF, granulocyte-macrophage colony stimulating factor; WBC, white blood cells.

Fig 1: Outline of the experimental strategy. Molecular rescue of VH-CDR3 sequences was accomplished from patient tumor B-cells of different chronic lymphoproliferative disorders. Amplified sequences were cloned into a mammalian multigenic vector (pRC111) which independently co-expresses

interleukin-2 and tumor-specific VH-CDR3 sequences. pRC111 vectors containing cloned VH-CDR3 sequences were injected in outbred mice. Sera obtained at different time-points after DNA injection were challenged with the original patients' tumor B-cells and tested by FACS analysis.

Fig 2: Nucleotide (lower case) and deduced amino acid (upper case) sequence of cDNA encoding human heavy chain CDR3 variable regions from 3 different patients. Bold: part of the primer sequences. Gray box: deduced CDR3 sequence.

Fig 3: Semi quantitative RT-PCR analysis of mIL2 transcription in muscle of pRC111-PA injected mice. Results are obtained using 500, 50 and 5 ng of total RNA prepared from four animals (named 1, 2, 3, 4) at 1 week post-injection. Mouse beta-actin (β Act) and mouse IL2 sequences were amplified as described in the text. Positive samples show a mIL2-specific 158-bp amplified fragment. C2 and C4 (PA 2 and PA 4 contro-lateral muscles, respectively) were injected with empty pRC100 plasmid vector (negative control). First line: molecular weight marker (162 and 79 bp). β -act: mouse beta-actin specific 154-bp amplified fragment.

Fig 4: Reactivity of Abs induced by DNA vaccine containing VH-CDR3 region from patient PA with the patient tumor cells, as assessed by fluorescence activator cell sorting (FACS). The serum (diluted 1:50) from mice immunized with pRC111-PA was incubated with their target tumor cells (PA682) (A, B) or with tumor cells from patient BA (C).

The control serum was from the same pre-injected mice. After incubation, cells were washed and bound antibodies detected by FITC-conjugated goat anti-mouse serum, using a FACS-Scan. Results of a representative sample (PA) are displayed as peak presentations obtained with (A) pre-immune and (B) immune serum (6-weeks following pRC111-PA injection). The internal control peak (B) shows the baseline reactivity of detecting goat fluoresceinated anti-mouse antibody alone. C: FACS analysis of pRC111-PA antiserum challenged with BA tumor cells.

Example 1

Molecular rescue of VH-CDR3 sequences from patient tumor B-cells of chronic lymphoproliferative disorders

The aim of this study was to demonstrate the effectiveness of the short hypervariable region (VH-CDR3) of the idiotypic immunoglobulin, expressed on B-cells of chronic B-lymphoproliferative disorders, in allowing rapid cloning and specific immune response through naked DNA immunization.

Two EBV transformed cell lines (AS283A and PA682) derived from two non-Hodgkin's B-lymphoma patients' cells, and one frozen peripheral blood sample from a hairy-cell leukemia patient (BA), were used as sources of CDR3 sequences.

The WBC at diagnosis in the peripheral blood of the HCL-V patient was very high ($130.000/\text{mm}^3$) and the percentage of the leukemia cells >95%. The cell lines used as a source material for the CDR3 sequences were clonal cells whose origin from the primary lymphomas of the patients was previously established (Gaidano et al., In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions and heterogeneity in Epstein-Barr virus infection. *Leukemia*, 7: 1621-1629, 1993).

The identity of their CDR3 regions with the sequences used for DNA vaccination was established by comparing the sequence of the amplified fragments obtained from the tumor cells with the sequence of the plasmids used for vaccination (see below). The same cells were also used to determine the presence of antibodies reactive with the idiotypes in treated mice (see below).

Total RNA was purified from patients' cells and cDNA prepared using random hexamers. The amplification was performed in two steps, as described in the Example 2. The use of RNA and of a two step PCR procedure allowed high sensibility and specificity of yielded products.

Amplified variable regions and CDR3s were analyzed on a 2% SeaKem agarose gel (FMC, Rockland, ME). Bands were purified by QIAEX gel extraction kit (Qiagen Inc., GmbH) according to manufacturer's instructions. The purified VH-CDR3 cDNAs were directly cloned into the *NheI*/*NotI* sites of one transcriptional cassette of pRC100-related plasmid vectors, with (pRC111) or without (pRC101) mouse IL2 (mIL2) cDNA in the second transcriptional cassette (Table 1) (Ciafrè et al. *Plasmid*, 40: 84-89, 1998). cDNA fragments were subsequently sequenced

by dideoxy chain termination method using T7 DNA polymerase (Sequenase Version 2.0, USB).

Plasmid DNA was purified by Qiagen Plasmid Mega Kit (Cat. No. 12181) according to manufacturer's protocol, in order to avoid use of a mutagen (ethidium bromide) or CsCl gradient, both included in the standard protocol for plasmid purification. The DNA plasmid was resuspended at 1.2 ug/ul in sterile 225 mM NaCl (1.5 x normal saline).

These multigenic vectors incorporate two different transcription cassettes controlled by two independent promoters (CMV and RSV promoters/enhancers) and allows co-expression of a cytokine, human IL2 or GM-CSF or a toxin, together with a specific antigen, the individual VH-CDR3 peptide (pRC111) (Fig 1).

Table 1. DNA immunization constructs, encoded antigenic proteins and immune modulator

Plasmid	Gene 1				Gene 2		
	Promoter	Cloning sites	Gene	Source	Promoter	Cloning sites	Cytokine
PRC100	RSV	NheI-NotI	N	-	CMV	XhoI	N
PRC101	RSV	NheI-NotI	VH-CDR3	BA HCL	CMV	XhoI	N
PRC101	RSV	NheI-NotI	VH-CDR3	PA B-NHL	CMV	XhoI	N
PRC101	RSV	NheI-NotI	VH-CDR3	AS B-NHL	CMV	XhoI	N
PRC110	RSV	NheI-NotI	N	-	CMV	XhoI	m IL2
PRC111	RSV	NheI-NotI	VH-CDR3	BA HCL	CMV	XhoI	m IL2
PRC111	RSV	NheI-NotI	VH-CDR3	PA B-NHL	CMV	XhoI	m IL2
PRC111	RSV	NheI-NotI	VH-CDR3	AS B-NHL	CMV	XhoI	m IL2
PRC112	RSV	NheI-NotI	NS3	HCV strain H	CMV	XhoI	m IL2

Abbreviations:

RSV = Rous sarcoma virus LTR promoter/enhancer; VH-CDR3 = complementary determining region 3 of the variable immunoglobulin heavy chain; HCL = hairy cells leukemia; NHL = non-Hodgkin's B cell lymphoma; BA/PA/AS = patients CDR3 sources; CMV = cytomegalovirus promoter/enhancer; m IL2 = murine interleukin 2; N = none; HCV = Hepatitis C virus; NS3 = HCV non structural protein 3, 4403-4829 fragment

Example 2

VH-CDR3 amplification

The amplification was performed in two steps, using the following family specific PCR primers for human heavy chain CDR3 variable region: A) First step: Upstream: **VH₁₋₃₋₅₋₇** 5'-(C,G)AG GTG CAG CTG GTG (C,G)AG TCT -3'; **VH₂** 5'- CAG (G,A)TC ACC TTG AAG GAG TCT -3'; **VH₄** 5'- CAG GTG CAG CTG CAG GAG TCG -3'; **VH₆** 5'- CAG GTA CAG CTG CAG CAG TCA -3'. Downstream: **RHmu** 5'- CAC GCT GCT CGT ATC CGA CGG -3'. Upstream primers were derived from (Deane et al. Brit. J. Haematol., 77: 274-281, 1991). Downstream primer RHmu was designed to anneal with the 5' terminus of the constant region *mu* of the human heavy chain. B).

Second step: Upstream: (eFR₃ derived) **eFW3** 5'-*TTT* G/CTAGC ATG CAC ACG GC(C,T) (G,C)TG TAT TAC TGT-3'. Downstream: (eLJH derived) **eJH** 5'-*TAT* GC/GGCCGC TTA TTA TGA GGA GAC GGT GAC C-3'. Upstream and downstream primers for the second step PCR were derived from (Ramasamy et al., Improved PCR method for detecting monoclonal immunoglobulin heavy-chain rearrangement in B-cell neoplasm. J. Clin. Pathol., 45: 770-775, 1992), with some modifications. As compared to published sequence, eJH annealing sequence extends 2 nucleotide at 3' end of eLJH and eFW3 annealing sequence extends 1 nucleotide at 5' end of eFR₃, in order to improve specificity and PCR conditions. Moreover, both primers for the second step of PCR amplification included sequences for restriction sites (eFW₃: NheI; eJH: NotI) (underlined), preceded by a short sequence (*italics*) for enhancing enzymatic cleavage efficiency (Ausubel et al. Current Protocols In Molecular Biology. New York: Wiley J and Sons Inc., 1992). Insertion of NheI and NotI restriction sites as 5' flushing ends of the

primers allowed the directional cloning of the amplified cDNAs in one transcriptional cassette of pRC110 vector (see below).

RNA was first isolated from cell lines and frozen clinical samples, as described (Chomczynski et al. *Anal. Biochem.*, 162: 156-159, 1987). Synthesis of cDNA was performed using a first-strand cDNA synthesis kit (Perkin Elmer), MuLV Reverse Transcriptase (Perkin Elmer) and random hexamers in a 20µl final volume; reaction conditions were 23°C 10 minutes, 42°C 45 minutes and 99°C 5 minutes. RT-PCR was performed in a final volume of 100µl with 15 pmol of each primer, 50µmol of deoxynucleotide triphosphate and 1U of AmpliTaq (Perkin Elmer); first step of amplification: 2 minutes at 96°C, followed by 5 cycles of 93°C for 1 minute, 65°C for 30 seconds, 72°C for 30 seconds; and 30 cycles of 93°C for 30 seconds, 65°C for 30 seconds, 72°C for 30 seconds. The second step of all PCRs (nested PCR) was performed with the hot-start procedure; reaction conditions were: 2 minutes at 96°C, followed by 10 cycles at 93°C for 30 seconds, 65°C for 30 seconds, 72°C for 15 seconds, and 20 cycles of 15 seconds for each step of denaturation, annealing and polymerization.

The amplified fragments were sequenced by the dideoxy chain termination method using T7 DNA polymerase (Sequenase Version 2.0, USB). The CDR3 regions, the number of the somatic mutations present as well as the germline sequences of the patients from which the leukemia/lymphoma cells were derived, were established by comparing the sequence of the amplified fragments to the most homologous germline sequences of the Ig V genes present in the Genbank databases of the NCBI and in the V BASE sequence directory of the MRC Center for Protein Engineering (Cambridge, UK). The softwares used were, respectively, the BLAST program and the Mac Vector 6.0.1 software (Oxford Molecular Group PLC, Oxford, UK).

Example 3

Animals and immunization protocols

Female Swiss mice about 8 weeks of age were used for immunization. Blood samples were obtained by tail bleeds, and serum was stored at -80°C for subsequent assay. DNA injection was performed into the quadriceps muscle

(intramuscular injection, i.m.) using a disposable, plastic insulin syringe and 29G x ½" needle (Becton Dickinson, ref. N°324804 micro-fine). Experimental groups received i.m. injections of 80 µg of pRC100 derived vectors encoding either only for CDR3 region (pRC101) or for mIL2 only (pRC110) or for both (pRC111) (Fig 1 and Table 1).

As control two other groups of mice were injected, under the same experimental procedure, with empty plasmid (pRC100) or with pRC100 derived vector encoding for mIL2 and for an HCV non-structural antigen (NS-3) (pRC112). Two injections were performed respectively at the beginning of the experiment (T0) and three weeks after the first injection (T3). The third injection was performed 6 or 16 weeks after the beginning of experiments (T6 or T16). Mice were bled the day before each injection and at the following time points: T6, T9 and T19 (6, 9 and 19 weeks after the first injection, respectively).

Example 4

Anti VH-CDR3 antibody detection

The production of antibodies by treated mice was assessed by FACS analysis, matching the sera with the EBV transformed B-cell lines (from patients PA and AS) or with thawed peripheral blood mononuclear cells (from patient BA), followed by incubation with fluorescein conjugated (FITC) goat anti-mouse antiserum (Coulter Clone, GAM-FITC) and detected by means of fluorescence activated flow cytometer (FACS) (Profile II FACS, Coulter). All staining steps were performed in PBS supplemented with FCS 5%, NHS 1% and NaN₃ 0.1% (staining medium). 2x10⁵ cells were incubated 40 minutes in staining medium to reduce non specific binding, followed by a first step of staining with treated mouse serum diluted 1:50 or 1:20 in staining medium, in a final volume of 100 µl, 30 minutes on ice. After 3 washes in staining medium, 10⁵ cells were added as an internal control (only for PA and AS) and cells underwent a second step of staining with 1:500 FITC goat anti mouse serum in a final volume of 100 µl. After further 30 min, cells were washed thoroughly, resuspended in staining medium, and their fluorescence was read using a Profile II FACS.

When performed using serum samples obtained before the first immunization (T0), FACS analysis usually gives a single peak, in which the internal control and the double stained cells overlapped. Samples were selected as positive for anti-CDR3 antibody when two peaks were observed: the first one overlapped with that obtained with T0 sample and corresponded to the internal control (i.e. the cells that were added after the staining with the immune serum, usually 1/3 of total cells), while the second, high fluorescence peak was due to those cells that had undergone the staining with "immune" serum (2/3 of total cells). A fivefold higher mean fluorescence value for the "high fluorescence peak" with respect to the internal control was chosen as threshold value of positivity for anti-idiotypic antibody. For each individual mouse, all samples (T0-T19) were measured at the same time.

The specificity of the immune response developed against each individual VH-CDR3 sequence was evaluated matching sera from each group of animals with cells of the other patients and analyzed by FACS under the same technical protocol (e.g. sera from pRC111-PA injected mice were matched with BA and AS cells).

Example 5

IL2 is produced at the site of naked DNA injection

In a preliminary trial, 8 two-months-old Swiss mice were intramuscularly (i.m.) injected both with pRC111-PA vector coding for mouse IL2 and VH-CDR3 from patient PA, and with empty pRC100 plasmid in the controlateral muscles as described in the Example 3. Transcription was evaluated at the site of injection by semi quantitative RT-PCR analysis, after 2 days and 1 week.

Total cellular RNA was extracted from excised muscles as described (Chomezynski P., et al., *Single step method of RNA isolation by acid guanidinium thiocyanato-phenol-chloroform extraction*. Anal. Biochem., 162: 156-159, 1987). 500, 50 and 5 ng of total RNA were reverse transcribed using 500 ng oligo (dT) primers (GIBCO-BRL), 1 mM [dNTP] (Promega), 10 U AMV-RT (Promega) and 20 U RNAsin (Promega), in 20 µl final volume.

Incubation conditions were 42°C 45 min., 99°C 5 min. Mouse β -actin and mouse IL2 sequences were amplified using 5 μ l of each cDNA preparation, 1U Taq polymerase (Promega), 2 mM $MgCl_2$ (Promega), 200 μ M [dNTPs], 20 pmoles each primer, in 50 μ l final volume. Mouse β -actin primers: FW: TgAgg CTCTT TTCCA gCCT; RV: CTAga AgCAC TTgCg gTgCA.

Mouse IL2 primers: FW: CACTT CAAgC TCTAC AgCgg A; RV: AAAAT TTgAA ggTgA gCATC C. Amplification was performed by 38 cycles at 94°C for 1 min., 56°C for 1 min., 72°C for 1 min.

Fig 3 shows results obtained in 4 animals (named 1, 2, 3, 4) 1 week following injection of, respectively, pRC111-PA in the left quadriceps muscle and pRC100 in the controlateral muscle (named C2 and C4). Even if to different extents, IL2 transcription was detected in all pRC111-PA injected muscles but no endogenous IL2 expression was demonstrated in pRC100 injected controlateral muscles. Same results were obtained at 2 days after injection (4 animals).

Example 6

Naked DNA injection of pRC111 vectors coding for the individual VH-CDR3 results in immune response against the idiotypic Ig expressed on patient's tumor cells

Since human subjects that may potentially benefit from this therapeutic approach will have a broad range of MHC haplotypes, Swiss mice were chosen as test strain, given the fact that they are outbred and therefore display a variety of MHC haplotypes.

Thus, 8-week-old Swiss mice were i.m. injected with pRC101-PA (mIL2⁻) or pRC111-PA (mIL2⁺) vectors, in which VH-CDR3 from patient PA was cloned. As controls, three groups of mice were injected with either pRC100 (CDR3⁻, mIL2⁻ vector), or pRC110 (CDR3⁻, mIL2⁺ vector) (Ciafrè et al., A plasmid family containing two different expression cassettes suitable for immune modulation and genetic vaccination. Plasmid, 40: 84-89, 1998) or pRC112 (encoding for HCV non-structural antigen NS-3, mIL2⁺) (Papa et al., Development of a multigenic plasmid vector for HCV DNA immunization. Res. Virol. 149: 315-319, 1998) under the same experimental schedule, as described in the example 3.

At various time points after DNA injection, mouse were bled and the presence of anti-idiotypic antibodies was tested by means of cytofluorimetric analysis. For each individual mouse, all samples were measured at the same time.

Figure 4 shows the FACS analysis obtained with PA682 cells (patient PA) challenged by pre-immune (4A) and immune (4B) serum samples of a mouse vaccinated with pRC111-PA vector.

We also evaluated the ability of naked DNA encoding for the VH-CDR3 region to induce anti-idiotypic antibodies, and observed the effect of mIL2 on this response. Only 20% of mice injected with pRC101-PA (IL2⁻) produced measurable amounts of anti-idiotypic antibodies (Table 2). The injection of vector pRC111-PA (IL2⁺) resulted in production of Ig-specific antibodies in 56 % of mice. Thus, IL2 co-expressed with the antigen results in increase of efficiency of immunization. No specific antibodies were detected in mice injected with pRC100, pRC110 or pRC112 control vectors.

As shown in Table 2, the response was detected as early as 3 weeks after the first immunization, peaked soon after the second immunization and persisted over a considerably long span of time, since it was still detected after approximately five months. Furthermore, no decrease of titer of specific Igs was observed. As in the present experimental strategy, it is often found that a third injection of DNA did not always result in increase of the titer or of the number of animals that tested positive. Interestingly, the co-injection of IL2 increases the number of responding mice, but does not modify the kinetic of antibody production.

Table 2. Immune response evaluation against non-Hodgkin's lymphoma cells from patient PA.

Outbred Swiss mice were intramuscularly injected at T0, and 3 (T3) and 16 (T16) weeks later with different plasmid constructs. Sera were collected at 3 (T3), 6 (T6), 9 (T9), 16 (T16) and 19 (T19) weeks after the first injection. Lymphoma cells from patient PA were challenged by mouse sera and analyzed by FAC scanning. Results are expressed as percent of positive animals.

Plasmid	mIL2	Insert	Animals N.	Immune animals (%)				
				T3	T6	T9	T16	T19
pRC 100	-	-	15	0	0	0	0	0
pRC 100	+	-	15	0	0	0	0	0
pRC 112	+	HCV NS3	15	0	0	0	0	0
pRC 101-PA	-	PA VH-CDR3	15	13	20	20	13	0
pRC 101-PA	+	PA VH-CDR3	25	45	56	56	40	40

For abbreviations see Table 1

Example 7

Anti CDR3 responses can be obtained with different CDR3s

Two more points needed to be clarified in order to propose this approach for immunotherapy. The first was to demonstrate that such approach can be successful for several different VH-CDR3; the second was to show that the antibodies elicited really recognize a "private" epitope of the Ig, in order to minimize the possibility to generate a systemic self-reactive disease.

To address these points, in a new set of experiments the VH-CDR3 from 2 other patients (AS and BA) were cloned. Swiss mice were immunized with the resulting vectors pRC111-AS or BA, respectively, using the same protocol, as described in example 3. As it is shown in Table 3A, the rate of positive results obtained using 3 different CDR3s was similar. This observation confirmed that naked DNA immunization with vector pRC111 can result in anti-CDR3 response for several distinct CDR3s.

In order to address the second point, immune sera were also tested for ability to recognize cells obtained from the other patients (e.g., sera positive for anti CDR3-PA response were also matched with cells from patients AS and BA, and viceversa). This experiment allowed us to check the fine specificity of the antibody response. No cross reactivity towards the CDR3s different from the one used for immunization was found among sera that had tested positive (Fig. 4C and Table 3). This result confirms that no response against frame regions of the

CDR3s was elicited using this protocol, and therefore that the risk of spreading of the immune response towards systemic self-reactivity is possibly low.

Table 3. Specificity of anti-VH-CDR3 immune response versus lymphoproliferative cells from three different patients (PA, AS, BA).

Outbred Swiss mice were intramuscularly injected at T0, and 3 (T3) and 6 (T6) weeks later with different plasmid constructs. Sera were collected at 3 (T3), 6 (T6) and 9 (T9) weeks after the first injection.

Results are expressed as percent of positive sera determined by FACS analysis.

Plasmids	m IL2	CDR3	Patient's cells	Animals N.	Immune animals (%)		
					T3	T6	T9
A							
pRC 111-PA	+	PA	PA	5	20	60	60
pRC 111-AS	+	AS	AS	5	0	40	40
pRC 111-BA	+	BA	BA	5	NT	40	40
B							
pRC 111-PA	+	PA	AS-BA	5	0	0	0
pRC 111-AS	+	AS	PA-BA	5	0	0	0
pRC 111-BA	+	BA	PA-AS	5	0	0	0
C							
pRC 110	+	-	PA BA AS	5	0	0	0

A = Percent of sera from mice injected with pRC111-PA/AS/BA vectors reacting with patient tumor cells expressing the same VH-CDR3 (PA/AS/BA).

B = Specificity of immune response against each VH CDR3. Sera from animals injected with vector encoding each idiotypic were challenged with patients' cells expressing each of the three VH CDR3.

C = Control mice: sera from 5 mice injected with CDR3-free vector (pRC110) were challenged with patients' cells expressing each of the three VH CDR3.


NT = not tested.

CLAIMS

1. Use of DNA sequences, essentially coding for the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders, as therapeutic vaccines.
2. Use according to claim 1 characterized in that said vaccines are effective against chronic B-lymphoproliferative disorders expressing the surface idiotypic immunoglobulin in mammals, preferably in humans.
3. Use according to claim 1 characterized in that said DNA sequence is of mammalian origin, preferably human.
4. Use according to claim 1 characterized in that said DNA sequence codes for peptides having a length of 0-45 a.a., preferably of 7-45 a.a..
5. Use according to claim 4 characterized in that said DNA sequence is comprised between eFW3 and eJH sequences.
6. A recombinant plasmid expression vector suitable for expression of a DNA sequence in a mammalian and containing a DNA sequence operably linked thereto, characterized in that said DNA sequence essentially consists of the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders.
7. A recombinant plasmid expression vector according to claim 6 characterized in that the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders is the only antigenic agent which is expressed in vivo when said vaccine composition is administered to a mammalian.
8. A recombinant plasmid expression vector according to claim 6 characterized in that said vaccine is effective against chronic B-lymphoproliferative disorders expressing the surface idiotypic immunoglobulin in mammals, preferably in humans.
9. A recombinant plasmid expression vector according to claim 6 characterized in that said DNA sequence is of mammalian origin, preferably human.
10. A recombinant plasmid expression vector according to claim 6 characterized in that said DNA sequence codes for peptides having a length of 0-45 a.a., preferably of 7-45 a.a..

11. A recombinant plasmid expression vector according to claim 10 characterized in that said DNA sequence is comprised between eFW3 and eJH sequences.
12. A recombinant plasmid expression vector according to claim 6 characterized in that said DNA sequence consists of: (a) the gene coding for the hypervariable region (VH-CDR3) of the idiotypic immunoglobulin expressed on B-cells of chronic B-lymphoproliferative disorders and (b) upstream and downstream PCR primers.
13. A recombinant plasmid expression vector according to claim 12 characterized in that said upstream PCR primer is eFW3 and/or in that said downstream PCR primer are eJH and/or Rhmu.
14. A recombinant plasmid expression vector according to claim 6 characterized in that said recombinant plasmid expression vector also encodes for an immunomodulatory molecule.
15. A recombinant plasmid expression vector according to claim 12 characterized in that said immunomodulatory molecule is selected from IL-2, GM-CSF, IL-12, IL-6 and fragments from bacterial immunotoxins.
16. Use of a recombinant plasmid expression vector according to claim 6 as a therapeutic vaccine.
17. Use of a recombinant plasmid expression vector according to claim 6 for the manufacture of a vaccine effective against chronic B-lymphoproliferative disorders expressing the surface idiotypic immunoglobulin in mammals, preferably in humans.
18. A vaccine composition effective against chronic B-lymphoproliferative disorders expressing the surface idiotypic immunoglobulin in mammals, preferably in humans, characterized by containing a recombinant plasmid expression vector according to claim 6.
19. A vaccine composition according to claim 18 characterized by being in a form suitable form being administered parenterally, preferably intramuscularly.
20. A vaccine composition according to claim 19 characterized by being a water solution.
21. A vaccine composition according to claim 19 further containing customary excipients and adjuvants.

Fig. 1.A







Fig. 1.B

Immunoglobulin Heavy chain Variable Domain



First step primers:

Back: VH₁₋₃₋₅₋₇ 5'- (C,G)AG GTG CAG CTG GTG (C,G)AG TCT -3'
 VH₂ 5'- CAG (G,A)TC ACC TTG AAG GAG TCT -3'
 VH₄ 5'- CAG GTG CAG CTG CAG GAG TCG -3'
 VH₆ 5'- CAG GTA CAG CTG CAG CAG TCA -3'
Forward: RHm 5'- CAC GCT GCT CGT ATC CGA CGG -3'

Second step primers:

Back: eFW₃ 5'-TTT G/CTAGC ATG CAC ACG GC(C,T) (G,C)TG TAT TAC TGT-3'
 NheI
Forward: eJH 5'-TAT GC/GGCCGC TTA TTA TGA GGA GAC GGT GAC C-3'
 NotI

Fig. 2

A) CDR3 _H - sequence (Hairy Cell Leukemia)		
1	M	14
2	H	13
3	T	12
4	A	11
5	V	10
6	Y	9
7	Y	8
8	C	7
9	A	6
10	R	5
11	V	4
12	L	3
13	Y	2
14	Y	1
15	ATG	
16	CAC	
17	ACG	
18	GCT	
19	GTG	
20	TAT	
21	TAC	
22	TGT	
23	GCG	
24	AGA	
25	GTT	
26	TTG	
27	TAT	
28	TAC	
29	TAC	
30	TAC	
31	TAC	
32	TAC	
33	TAC	
34	TAC	
35	TAC	
36	TAC	
37	TAC	
38	TAC	
39	TAC	
40	TAC	
41	TAC	
42	TAC	
43	TAC	
44	TAC	
45	TAC	
46	TAC	
47	TAC	
48	TAC	
49	TAC	
50	TAC	
51	TAC	
52	TAC	
53	TAC	
54	TAC	
55	TAC	
56	TAC	
57	TAC	
58	TAC	
59	TAC	
60	TAC	
61	TAC	
62	TAC	
63	TAC	
64	TAC	
65	TAC	
66	TAC	
67	TAC	
68	TAC	
69	TAC	
70	TAC	
71	TAC	
72	TAC	
73	TAC	
74	TAC	
75	TAC	
76	TAC	
77	TAC	
78	TAC	
79	TAC	
80	TAC	
81	TAC	
82	TAC	
83	TAC	
84	TAC	
85	TAC	
86	TAC	
87	TAC	
88	TAC	
89	TAC	
90	TAC	
91	TAC	
92	TAC	
93	TAC	
94	TAC	
95	TAC	
96	TAC	
97	TAC	
98	TAC	
99	TAC	
100	TAC	
101	TAC	
102	TAC	
103	TAC	
104	TAC	
105	TAC	
106	TAC	
107	TAC	
108	TAC	
109	TAC	
110	TAC	
111	TAC	
112	TAC	
113	TAC	
114	TAC	
115	TAC	
116	TAC	
117	TAC	
118	TAC	
119	TAC	
120	TAC	
121	TAC	
122	TAC	
123	TAC	
124	TAC	
125	TAC	
126	TAC	
127	TAC	
128	TAC	
129	TAC	
130	TAC	
131	TAC	
132	TAC	
133	TAC	
134	TAC	
135	TAC	
136	TAC	
137	TAC	
138	TAC	
139	TAC	
140	TAC	
141	TAC	
142	TAC	
143	TAC	
144	TAC	
145	TAC	
146	TAC	
147	TAC	
148	TAC	
149	TAC	
150	TAC	
151	TAC	
152	TAC	
153	TAC	
154	TAC	
155	TAC	
156	TAC	
157	TAC	
158	TAC	
159	TAC	
160	TAC	
161	TAC	
162	TAC	
163	TAC	
164	TAC	
165	TAC	
166	TAC	
167	TAC	
168	TAC	
169	TAC	
170	TAC	
171	TAC	
172	TAC	
173	TAC	
174	TAC	
175	TAC	
176	TAC	
177	TAC	
178	TAC	
179	TAC	
180	TAC	
181	TAC	
182	TAC	
183	TAC	
184	TAC	
185	TAC	
186	TAC	
187	TAC	
188	TAC	
189	TAC	
190	TAC	
191	TAC	
192	TAC	
193	TAC	
194	TAC	
195	TAC	
196	TAC	
197	TAC	
198	TAC	
199	TAC	
200	TAC	
201	TAC	
202	TAC	
203	TAC	
204	TAC	
205	TAC	
206	TAC	
207	TAC	
208	TAC	
209	TAC	
210	TAC	
211	TAC	
212	TAC	
213	TAC	
214	TAC	
215	TAC	
216	TAC	
217	TAC	
218	TAC	
219	TAC	
220	TAC	
221	TAC	
222	TAC	
223	TAC	
224	TAC	
225	TAC	
226	TAC	
227	TAC	
228	TAC	
229	TAC	
230	TAC	
231	TAC	
232	TAC	
233	TAC	
234	TAC	
235	TAC	
236	TAC	
237	TAC	
238	TAC	
239	TAC	
240	TAC	
241	TAC	
242	TAC	
243	TAC	
244	TAC	
245	TAC	
246	TAC	
247	TAC	
248	TAC	
249	TAC	
250	TAC	
251	TAC	
252	TAC	
253	TAC	
254	TAC	
255	TAC	
256	TAC	
257	TAC	
258	TAC	
259	TAC	
260	TAC	
261	TAC	
262	TAC	
263	TAC	
264	TAC	
265	TAC	
266	TAC	
267	TAC	
268	TAC	
269	TAC	
270	TAC	
271	TAC	
272	TAC	
273	TAC	
274	TAC	
275	TAC	
276	TAC	
277	TAC	
278	TAC	
279	TAC	
280	TAC	
281	TAC	
282	TAC	
283	TAC	
284	TAC	
285	TAC	
286	TAC	
287	TAC	
288	TAC	
289	TAC	
290	TAC	
291	TAC	
292	TAC	
293	TAC	
294	TAC	
295	TAC	
296	TAC	
297	TAC	
298	TAC	
299	TAC	
300	TAC	
301	TAC	
302	TAC	
303	TAC	
304	TAC	
305	TAC	
306	TAC	
307	TAC	
308	TAC	
309	TAC	
310	TAC	
311	TAC	
312	TAC	
313	TAC	
314	TAC	
315	TAC	
316	TAC	
317	TAC	
318	TAC	
319	TAC	
320	TAC	
321	TAC	
322	TAC	
323	TAC	
324	TAC	
325	TAC	
326	TAC	
327	TAC	
328	TAC	
329	TAC	
330	TAC	
331	TAC	
332	TAC	
333	TAC	
334	TAC	
335	TAC	
336	TAC	
337	TAC	
338	TAC	
339	TAC	
340	TAC	
341	TAC	
342	TAC	
343	TAC	
344	TAC	
345	TAC	
346	TAC	
347	TAC	
348	TAC	
349	TAC	
350	TAC	
351	TAC	
352	TAC	
353	TAC	
354	TAC	
355	TAC	
356	TAC	
357	TAC	
358	TAC	
359	TAC	
360	TAC	
361	TAC	
362	TAC	
363	TAC	
364	TAC	
365	TAC	
366	TAC	
367	TAC	
368	TAC	
369	TAC	
370	TAC	
371	TAC	
372	TAC	
373	TAC	
374	TAC	
375	TAC	
376	TAC	
377	TAC	
378	TAC	
379	TAC	
380	TAC	
381	TAC	
382	TAC	
383	TAC	
384	TAC	
385	TAC	
386	TAC	
387	TAC	
388	TAC	
389	TAC	
390	TAC	
391	TAC	
392	TAC	
393	TAC	
394	TAC	
395	TAC	
396	TAC	
397	TAC	
398	TAC	
399	TAC	
400	TAC	
401	TAC	
402	TAC	
403	TAC	
404	TAC	
405	TAC	
406	TAC	
407	TAC	
408	TAC	
409	TAC	
410	TAC	
411	TAC	
412	TAC	
413	TAC	
414	TAC	
415	TAC	
416	TAC	
417	TAC	
418	TAC	
419	TAC	
420	TAC	
421	TAC	
422	TAC	
423	TAC	
424	TAC	
425	TAC	
426	TAC	
427	TAC	
428	TAC	
429	TAC	
430	TAC	
431	TAC	
432	TAC	
433	TAC	
434	TAC	
435	TAC	
436	TAC	
437	TAC	
438	TAC	
439	TAC	
440	TAC	
441	TAC	
442	TAC	
443	TAC	
444	TAC	
445	TAC	
446	TAC	
447	TAC	
448	TAC	
449	TAC	
450	TAC	
451	TAC	
452	TAC	
453	TAC	
454	TAC	
455	TAC	
456	TAC	
457	TAC	
458	TAC	
459	TAC	
460	TAC	
461	TAC	
462	TAC	
463	TAC	
464	TAC	
465	TAC	
466	TAC	
467	TAC	
468	TAC	
469	TAC	
470	TAC	
471	TAC	
472	TAC	
473	TAC	
474	TAC	
475	TAC	
476	TAC	
477	TAC	
478	TAC	
479	TAC	
480	TAC	
481	TAC	
482	TAC	
483	TAC	
484	TAC	
485	TAC	
486	TAC	
487	TAC	
488	TAC	
489	TAC	
490	TAC	
491	TAC	
492	TAC	
493	TAC	
494	TAC	
495	TAC	
496	TAC	
497	TAC	
498	TAC	
499	TAC	
500	TAC	
501	TAC	
502	TAC	
503	TAC	
504	TAC	
505	TAC	
506	TAC	
507	TAC	
508	TAC	
509	TAC	
510	T	





Fig. 4



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IT 01/00014

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SYRENGELAS A D ET AL: "DNA IMMUNIZATION INDUCES PROTECTIVE IMMUNITY AGAINST B-CELL LYMPHOMA" NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 2, no. 9, September 1996 (1996-09), pages 1038-1041, XP000996399 ISSN: 1078-8956 the whole document	1-21
X	STEVENSON F K ET AL: "IDIOTYPIC DNA VACCINES AGAINST B-CELL LYMPHOMA" IMMUNOLOGICAL REVIEWS, MUNKSGAARD, XX, vol. 145, 1 June 1995 (1995-06-01), pages 211-228, XP000670867 ISSN: 0105-2896 see whole doc. esp. p.212, 2.par.; p.214, 3.par.; pgs. 219-221	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

13 June 2001

Date of mailing of the international search report

25/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mueller, F

INTERNATIONAL SEARCH REPORT

Inte al Application No

PCT/IT 01/00014

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RINALDI M. ET AL.,: "Strategies to elicit anti-idiotypic immune response in B-lymphoma patients: peptide and genetic immunization" ADV. EXP. MED. BIOL., vol. 451, - 1998 pages 323-330, XP001005261 the whole document	1-21
Y	WEN Y.J. ET AL.,: "in-vivo immune responses o idiotype VH complementary-determining region 3 peptide vaccination in B-cell non-hodgkin's lymphoma" BRIT. J. OF HAEMATOLOGY, vol. 103, no. 3, - December 1998 (1998-12) pages 663-668, XP001005275 cited in the application the whole document	1-21
Y	WO 95 05853 A (HOWELL MEREDITH L ;CARSON DENNIS A (US); RAZ EYAL (US); UNIV CALIF) 2 March 1995 (1995-03-02) the whole document	1-21
A	CAMPBELL M. J ET AL: "IMMUNOTHERAPY OF ESTABLISHED MURINE B CELL LYMPHOMA. COMBINATION OF IDIOTYPE IMMUNIZATION AND CYCLOPHOSPHAMIDE" JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 141, no. 9, 1 November 1988 (1988-11-01), pages 3227-3233, XP002036673 ISSN: 0022-1767 see whole doc. esp. M&M; discussion	
A	XIONG S ET AL: "ENGINEERING VACCINES WITH HETEROLOGOUS B AND T CELL EPITOPES USING IMMUNOGLOBULIN GENES" NATURE BIOTECHNOLOGY,NATURE PUB. CO, NEW YORK, NY,US, vol. 15, no. 9, September 1997 (1997-09), pages 882-886, XP000918882 ISSN: 1087-0156	
A	IRVINE K R ET AL: "CYTOKINE ENHANCEMENT OF DNA IMMUNIZATION LEADS TO EFFECTIVE TREATMENT OF ESTABLISHED PULMONARY METASTASES" JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 156, 1996, pages 238-245, XP002030631 ISSN: 0022-1767	

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IT 01/00014

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505853 A	02-03-1995	AU 705889 B	03-06-1999
		AU 7639194 A	21-03-1995
		CA 2169635 A	02-03-1995
		EP 0714308 A	05-06-1996
		JP 9501936 T	25-02-1997
		US 5804566 A	08-09-1998
		US 5679647 A	21-10-1997
		US 5830877 A	03-11-1998
		US 5849719 A	15-12-1998
		US 5985847 A	16-11-1999
